Abstract
One of the most important therapeutic advances obtained in the field of rheumatology is the availability of the so-called bio(techno)logical drugs, which have deeply changed treatment perspectives in diseases such as rheumatoid arthritis and ankylosing spondylitis. According to the steadily increasing attention on gout, due to well-established prognostic and epidemiology implications, in the last 5 years, the same change of perspective has been observed also for this disease. In fact, several bio(techno)logical agents have been investigated both for the management of the articular gout symptoms, targeting mainly interleukin-1β, as well as urate-lowering therapies such as recombinant uricases. Among the IL-1β inhibitors, the majority of studies involve drugs such as anakinra, canakinumab, and rilonacept, but other compounds are under development. Moreover, other potential targets have been suggested, as, for example, the TNF alpha and IL-6, even if data obtained are less robust than those of IL-1β inhibitors. Regarding urate-lowering therapies, the recombinant uricases pegloticase and rasburicase clearly showed their effectiveness in gout patients. Also in this case, new compounds are under development. The aim of this review is to focus on the various aspects of different bio(techno)logical drugs in gouty patients.
Highlights
Gout is an autoinflammatory disease associated with increased blood levels of urate and due to deposition of monosodium urate crystals in and around joints [1]
The aim of this review is to focus on the various aspects of different bio(techno)logical drugs in gouty patients
Several bio(techno)logical drugs targeting particular points of gout and urate synthesis cascade have been approved for gout treatment by the US Food and Drug Administration and/or by the European Medicines Agency
Summary
Gout is an autoinflammatory disease associated with increased blood levels of urate and due to deposition of monosodium urate crystals in and around joints [1]. The prevalence of this condition is steadily increasing and gout is becoming one of the most common causes of inflammatory arthritis in industrialised countries [2,3,4,5,6,7]. Joints are the typical target of the disease and articular gout attacks are between the most painful conditions described [8]. Several biotechnological drugs have been employed and approved for gout treatment. This review is focused on the analysis of these treatments that potentially could reduce gout burden and the unmet needs of its pharmacological approach
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
